SubHero Banner

Isentress® HD (raltegravir) – New formulation approval

May 30, 2017 – Merck announced the FDA approval of Isentress HD (raltegravir) once daily film-coated tablets, in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients, and pediatric patients weighing at least 40 kg, who are treatment-naïve or virologically suppressed on an initial regimen of Isentress 400 mg twice daily.

Download PDF